

FORM 7**MONTHLY PROGRESS REPORT**

Name of Listed Issuer: EVI Global Group Developments Corp. (the "Issuer").

Trading Symbol: EVI

Number of Outstanding Listed Securities: 38,858,000

Date: February 5, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Due to the proposed change of business from a mining issuer to a life sciences issuer announced through the acquisition of Borganic Consulting Inc. on October 12, 2018, trading activity of the issuer has been halted by the Canadian Securities Exchange ("CSE"). Management of EVI Global is currently

working with the CSE to meet all required regulatory approvals and customary closing conditions.

2. Provide a general overview and discussion of the activities of management.

Management of EVI Global is currently working with the CSE to meet all required regulatory approvals and customary closing conditions associated with the proposed acquisition of Borganic Consulting Inc. and the deemed change of business the acquisition creates.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None to report

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On October 12, 2018 the issuer announced that in connection with the letter of intent with Borganic Consulting Inc. ("Borganic") previously announced on September 6, 2018, it has entered into a definitive share exchange agreement with Borganic under which the Company has agreed to acquire all the issued and outstanding shares of Borganic in exchange for an aggregate of 30,000,000 common shares of the Company being 43.57% of the Company's total issued and outstanding shares. The share exchange agreement remains subject to a number of conditions, including but not limited to the approval of the Canadian Securities Exchange ("CSE"), receipt of all other required regulatory approvals and customary closing conditions.

Borganic is focused on the commercial extraction of cannabidiol ("CBD") from industrial hemp. Borganic has secured an exclusive joint venture agreement with UK based Dragonfly Biosciences, LLC ("Dragonfly") to build a CBD extraction facility to service the European Union. Dragonfly's 2018 harvest of 420 hectares is expected to produce a minimum of 4.5 million grams of CBD.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

On October 12, 2018 the issuer announced that in connection with the letter of intent with Borganic Consulting Inc. ("Borganic") previously announced on September 6, 2018, it has entered into a definitive share exchange agreement with Borganic under which the Company has agreed to acquire all the issued and outstanding shares of Borganic in exchange for an aggregate of 30,000,000 common shares of the Company being 43.57% of the Company's total issued and outstanding shares. The share exchange agreement remains subject to a number of conditions, including but not limited to the approval of the Canadian Securities Exchange ("CSE"), receipt of all other required regulatory approvals and customary closing conditions.

Borganic is focused on the commercial extraction of cannabidiol ("CBD") from industrial hemp. Borganic has secured an exclusive joint venture agreement with UK based Dragonfly Biosciences, LLC ("Dragonfly") to build a CBD extraction facility to service the European Union. Dragonfly's 2018 harvest of 420 hectares is expected to produce a minimum of 4.5 million grams of CBD.

8. Describe the acquisition of new customers or loss of customers.

None to report

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None to report

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None to report

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None to report

14. Provide details of any securities issued and options or warrants granted.

None to report

15. Provide details of any loans to or by Related Persons.

None to report

16. Provide details of any changes in directors, officers or committee members.

None to report

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None to report

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated February 5, 2019.

Joel Leonard
 Name of Director or Senior
 Officer
 DocuSigned by:
Joel Leonard
 Signature
Director, CFO
 Official Capacity

Issuer Details		For Month	Date of Report
Name of Issuer		End	YY/MM/D
EVI Global Group Developments Corp.		January 2019	19/02/05
Issuer Address			
10 th Floor, 595 Howe St.			
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.	
Vancouver	()	()	
Contact Name	Contact Position	Contact Telephone No.	
Joel Leonard	Director, CFO	778-838-3692	
Contact Email Address	Web Site Address		
accounting@jclpartners.ca	www.stillcanna.com		